Sign in to view content

ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD

Raj K. Maturi, MD

Video
Published 2023

Related

Episode 9: Rate of Macular Atrophy in HARBOR Study with Dr. SriniVas Sadda
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Episode 25: RIVAL Study: Ranibizumab vs Aflibercept in T&E for wet AMD with Dr. Mark Gillies
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019

Category: AMD-Neovascular

See more